Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions

The introduction of vedolizumab, a lymphocyte adhesion inhibitor, has expanded the relatively limited therapeutic armamentarium available for Crohn’s disease and ulcerative colitis. Despite its effectiveness, both primary nonresponse and secondary loss of response to vedolizumab do occur, as is obse...

Descripción completa

Detalles Bibliográficos
Autores principales: Ward, Mark G., Sparrow, Miles P., Roblin, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5949937/
https://www.ncbi.nlm.nih.gov/pubmed/29774052
http://dx.doi.org/10.1177/1756284818772786

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5949937/
https://www.ncbi.nlm.nih.gov/pubmed/29774052
http://dx.doi.org/10.1177/1756284818772786

Ejemplares similares